VCYT News and Press, Veracyte Inc. From 09/02/23

2023-09-02 06:15:00 ET The aim of growth investing is to build significant wealth. Targeting companies that are briskly growing revenue can be a lucrative approach to investing. In the past five years, the genetic diagnostics company Veracyte (NASDAQ: VCYT) has produced cumulati...

Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Conference on Tuesday, September 12, at 4:15 p.m. Eastern Time. ...

New data are from a retrospective analysis of the Phase 2 STREAM trial Veracyte, Inc . (Nasdaq: VCYT) announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s Decipher Genomics Resource for Intellig...

2023-08-17 09:00:00 ET Summary Veracyte posted Q2 FY'23 earnings with continued growth in revenues and cash collections. The company's Decipher acquisition has shown positive results, with an increase in testing volumes. Despite potential investment value, uncertainties remain...

Awards mark Veracyte’s 10 th consecutive honor in the Bay Area and inaugural recognition in San Diego Veracyte, Inc . (Nasdaq: VCYT) announced that its South San Francisco and San Diego offices have been named top workplaces. Veracyte’s South San Francisco location h...

2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...

2023-08-08 22:05:21 ET Veracyte, Inc. (VCYT) Q2 2023 Earnings Conference Call August 08, 2023, 16:30 ET Company Participants Shayla Gorman - Director, IR Marc Stapley - CEO & Director Rebecca Chambers - EVP & CFO Conference Call Participants M...

2023-08-08 16:43:06 ET Veracyte press release ( NASDAQ: VCYT ): Q2 GAAP EPS of -$0.12 beats by $0.04 . Revenue of $90.32M (+24.0% Y/Y) beats by $7.23M . The company is raising full-year 2023 total revenue guidance to $342 million to $350 million vs $335.77M con...

Grew Total Revenue to $90.3 million, an Increase of 24% Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2023. “We delivered outstanding second quarter results, ...

2023-08-07 17:35:56 ET Veracyte ( NASDAQ: VCYT ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is -$0.14 (-7.7% Y/Y) and the consensus Revenue Estimate is $83.09M (+14.0% Y/Y). Over the last 1 year, ...